In 2011, the OFT found that Reckitt Benckiser had abused a dominant position in the market by withdrawing the supply of prescription packs of Gaviscon Original Liquid to pharmacists.
The Competition and Markets Authority (CMA) has evaluated the impact of this decision. This report, which has been subject to independent academic review, outlines the findings.
- assesses the potential for generic competition in this market without the withdrawal
- analyses the direct impact of the OFT’s decision
- estimates the value of saving to the NHS that might have been realised without the withdrawal